NVSEF
Novartis AG
OTC Markets OTCPKUSDEQUITY
Healthcare
DELAYED
Sell
-52/100
Last price
134.22
▼ 0.31 (0.23%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
134.53
Day high
140.93
Day low
140.93
Volume
1.21K
Market cap
$255.11B
P/E (TTM)
20.21
52W range
120.00 – 171.29
Trailing performance
Returnvs SPY
1W
-7.40%
-9.3%
1M
-18.28%
-19.4%
3M
-16.11%
-20.6%
6M
-13.34%
-31.5%
YTD
-2.74%
-17.0%
1Y
+4.89%
-11.5%
3Y
+38.15%
-44.1%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on NVSEF open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
40.12M
Total on file
Fundamentals
Market cap$255.11B
Enterprise value$296.91B
Revenue (TTM)$56.69B
Gross profit$42.51B
EBITDA$23.10B
Net income$12.76B
EPS (TTM)$6.64
Free cash flow$11.90B
Total cash$7.62B
Total debt$49.01B
Book value / share$21.86
Shares outstanding1.90B
Float1.86B
Short % of float—
Dividend yield3.53%
Beta (5Y)0.47
Valuation & profitability ratios
Trailing P/E20.21
Forward P/E—
PEG ratio3.15
Price / sales—
Price / book6.14
EV / revenue5.24
EV / EBITDA12.86
Gross margin74.98%
Operating margin34.62%
Profit margin22.50%
Return on equity30.35%
Return on assets10.25%
Debt / equity116.85
Current ratio0.86
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $56.67B | $51.72B | $46.66B | $43.46B | +9.6% |
| Operating revenue | $54.53B | $50.32B | $45.44B | $42.21B | +8.4% |
| Cost of revenue | $13.70B | $12.83B | $12.47B | $11.58B | +6.8% |
| Gross profit | $42.98B | $38.90B | $34.19B | $31.88B | +10.5% |
| Research & development | $11.20B | $10.02B | $11.37B | $9.17B | +11.8% |
| Selling, general & admin | $13.25B | $12.57B | $12.52B | $12.19B | +5.4% |
| Total operating expense | $25.33B | $24.35B | $24.42B | $23.93B | +4.0% |
| Operating income | $17.64B | $14.54B | $9.77B | $7.95B | +21.3% |
| Net interest income | -$980.00M | -$686.00M | -$419.00M | -$574.00M | -42.9% |
| Pre-tax income | $16.35B | $13.64B | $9.12B | $7.18B | +19.9% |
| Tax provision | $2.38B | $1.70B | $551.00M | $1.13B | +40.2% |
| Net income | $13.98B | $11.94B | $14.85B | $6.96B | +17.1% |
| Net income to common | $13.98B | $11.94B | $14.85B | $6.96B | +17.1% |
| Basic EPS | 7.21 | 5.92 | 7.15 | 3.19 | +21.8% |
| Diluted EPS | 7.15 | 5.87 | 7.10 | 3.17 | +21.8% |
| EBIT | $17.50B | $14.65B | $9.98B | $7.98B | +19.5% |
| EBITDA | $22.82B | $20.71B | $18.25B | $14.68B | +10.2% |
| Basic shares | 1.94B | 2.02B | 2.08B | 2.18B | -3.9% |
| Diluted shares | 1.96B | 2.04B | 2.09B | 2.20B | -3.9% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $11.44B | $11.46B | $13.39B | $7.52B | — | -0.2% |
| Cash & short-term investments | $11.53B | $13.35B | $13.96B | $18.61B | — | -13.6% |
| Accounts receivable | $8.94B | $7.42B | $7.11B | $8.07B | — | +20.4% |
| Inventory | $6.27B | $5.72B | $5.91B | $7.17B | — | +9.5% |
| Total current assets | $30.46B | $29.70B | $30.48B | $36.91B | — | +2.5% |
| Property, plant & equipment | $12.35B | $10.87B | $10.92B | $12.20B | — | +13.6% |
| Goodwill & intangibles | $54.98B | $51.67B | $50.22B | $60.95B | — | +6.4% |
| Total assets | $110.95B | $102.25B | $99.94B | $117.45B | — | +8.5% |
| Total current liabilities | $27.28B | $28.69B | $26.39B | $28.66B | — | -4.9% |
| Current debt | $5.52B | $8.09B | $6.08B | $5.88B | — | -31.7% |
| Long-term debt | $27.93B | $21.37B | $18.44B | $20.24B | — | +30.7% |
| Total debt | $35.38B | $31.26B | $26.35B | $27.91B | — | +13.2% |
| Total liabilities | $64.40B | $58.12B | $53.20B | $58.03B | — | +10.8% |
| Retained earnings | — | $46.56B | $49.65B | $63.54B | $70.99B | — |
| Shareholder equity | $46.13B | $44.05B | $46.67B | $59.34B | — | +4.7% |
| Working capital | $3.18B | $1.01B | $4.09B | $8.25B | — | +214.4% |
| Net tangible assets | -$8.85B | -$7.63B | -$3.55B | -$1.60B | — | -16.0% |
| Shares issued | 2.11B | 2.19B | 2.28B | 2.40B | — | -3.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $13.97B | $11.94B | $8.57B | $6.05B | +17.0% |
| Depreciation & amortisation | $5.33B | $6.07B | $8.28B | $6.71B | -12.3% |
| Stock-based compensation | $1.10B | $1.04B | $865.00M | $791.00M | +5.0% |
| Change in working capital | -$1.58B | -$706.00M | -$369.00M | -$796.00M | -123.4% |
| Operating cash flow | $19.14B | $17.62B | $14.46B | $14.24B | +8.7% |
| Capital expenditure | -$3.90B | -$3.81B | -$2.75B | -$2.24B | -2.3% |
| Investing cash flow | -$4.88B | -$7.51B | $5.60B | $1.47B | +35.1% |
| Share buybacks | -$9.21B | -$8.33B | -$8.72B | -$10.65B | -10.6% |
| Dividends paid | -$7.82B | -$7.62B | -$7.25B | -$7.51B | -2.5% |
| Financing cash flow | -$14.87B | -$11.74B | -$14.28B | -$20.56B | -26.6% |
| Free cash flow | $15.24B | $13.80B | $11.71B | $12.00B | +10.4% |
| End cash position | $11.44B | $11.46B | $13.39B | $7.52B | -0.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $14.95B | $13.52B | $13.86B | $14.36B | $14.84B | — | +10.6% |
| Operating revenue | $14.41B | $13.11B | $13.34B | $13.91B | $14.05B | — | +9.9% |
| Cost of revenue | $3.71B | $3.46B | $3.61B | $3.54B | $3.32B | — | +7.3% |
| Gross profit | $11.24B | $10.06B | $10.25B | $10.82B | $11.51B | — | +11.7% |
| Research & development | $2.85B | $2.74B | $3.16B | $2.94B | $2.73B | — | +3.9% |
| Selling, general & admin | $3.24B | $3.14B | $3.44B | $3.31B | $3.44B | — | +3.2% |
| Total operating expense | $6.49B | $5.83B | $6.63B | $6.32B | $6.65B | — | +11.3% |
| Operating income | $4.75B | $4.24B | $3.62B | $4.50B | $4.86B | — | +12.2% |
| Net interest income | -$479.00M | -$393.00M | -$96.00M | -$301.00M | -$330.00M | — | -21.9% |
| Pre-tax income | $4.27B | $3.84B | $3.22B | $4.20B | $4.53B | — | +11.2% |
| Tax provision | $1.01B | $683.00M | $814.00M | $266.00M | $507.00M | — | +48.2% |
| Net income | $3.26B | $3.16B | $2.41B | $3.93B | $4.04B | — | +3.4% |
| Net income to common | $3.26B | $3.16B | $2.41B | $3.93B | $4.04B | — | +3.4% |
| Basic EPS | 1.71 | 1.65 | 1.26 | — | 2.07 | 1.83 | +3.6% |
| Diluted EPS | 1.71 | 1.65 | 1.25 | — | 2.06 | 1.82 | +3.6% |
| EBIT | $4.73B | $4.18B | $3.52B | $4.48B | $4.82B | — | +13.1% |
| EBITDA | $6.13B | $5.41B | $5.07B | $5.84B | $6.08B | — | +13.3% |
| Basic shares | 1.91B | 1.91B | 1.91B | — | 1.95B | 1.97B | -0.2% |
| Diluted shares | 1.91B | 1.92B | 1.93B | — | 1.96B | 1.98B | -0.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $7.62B | $6.88B | $11.44B | $9.56B | $6.66B | — | +10.7% |
| Cash & short-term investments | $7.69B | $6.98B | $11.53B | $9.75B | $7.00B | — | +10.2% |
| Accounts receivable | $9.64B | $9.39B | $8.94B | $8.84B | $9.06B | — | +2.7% |
| Inventory | $6.22B | $6.29B | $6.27B | $6.42B | $6.31B | — | -1.0% |
| Total current assets | $27.35B | $26.61B | $30.46B | $28.20B | $25.94B | — | +2.8% |
| Property, plant & equipment | $12.27B | $12.24B | $12.35B | $11.99B | $11.83B | — | +0.2% |
| Goodwill & intangibles | $68.84B | $67.03B | $54.98B | $54.59B | $54.79B | — | +2.7% |
| Total assets | $122.03B | $118.53B | $110.95B | $107.29B | $104.39B | — | +3.0% |
| Total current liabilities | $31.75B | $31.37B | $27.28B | $32.00B | $31.71B | — | +1.2% |
| Current debt | $9.59B | $7.62B | $5.52B | $7.52B | $8.31B | — | +25.9% |
| Long-term debt | $37.49B | $37.45B | $27.93B | $22.60B | $22.47B | — | +0.1% |
| Total debt | $49.01B | $47.00B | $35.38B | $32.02B | $32.64B | — | +4.3% |
| Total liabilities | $80.09B | $79.61B | $64.40B | $62.54B | $62.34B | — | +0.6% |
| Retained earnings | $39.65B | $37.25B | — | $43.51B | $41.53B | $39.84B | +6.4% |
| Shareholder equity | $41.54B | $38.51B | $46.13B | $44.33B | $41.98B | — | +7.9% |
| Working capital | -$4.40B | -$4.77B | $3.18B | -$3.80B | -$5.78B | — | +7.8% |
| Net tangible assets | -$27.30B | -$28.52B | -$8.85B | -$10.26B | -$12.81B | — | +4.3% |
| Shares issued | 1.90B | 2.03B | 2.11B | 1.92B | 2.07B | — | -6.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | $3.26B | $3.16B | $2.40B | $3.93B | $4.02B | — | +3.2% |
| Depreciation & amortisation | $1.40B | $1.23B | $1.55B | $1.36B | $1.26B | — | +14.0% |
| Stock-based compensation | $267.00M | $303.00M | $299.00M | $268.00M | $267.00M | — | -11.9% |
| Change in working capital | $232.00M | -$787.00M | -$1.59B | $1.34B | $442.00M | — | +129.5% |
| Operating cash flow | $5.88B | $3.68B | $2.26B | $6.57B | $6.66B | — | +60.0% |
| Capital expenditure | -$758.00M | -$807.00M | -$1.02B | -$831.00M | -$558.00M | — | +6.1% |
| Investing cash flow | -$3.10B | -$11.74B | -$2.10B | -$860.00M | -$2.24B | — | +73.5% |
| Share buybacks | -$1.20B | -$1.88B | -$1.48B | -$2.30B | -$2.71B | — | +36.1% |
| Dividends paid | -$2.87B | -$6.20B | $0 | — | -$2.48B | -$5.33B | +53.7% |
| Financing cash flow | -$2.02B | $3.58B | $1.68B | -$2.79B | -$5.21B | — | -156.4% |
| Free cash flow | $5.12B | $2.87B | $1.25B | $5.74B | $6.11B | — | +78.6% |
| End cash position | $7.62B | $6.88B | $11.44B | $9.56B | $6.66B | — | +10.7% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $14.65B | +2.0% |
| Next quarter | — | — | $14.99B | +8.2% |
| Current year | — | — | $57.69B | +1.8% |
| Next year | — | — | $61.39B | +6.4% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders2.11%
Held by institutions46.01%
Institutions holding994
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
139.76
-3.96% from price
SMA 20
139.15
-3.55% from price
SMA 50
149.94
-10.48% from price
SMA 100
149.57
-10.27% from price
SMA 200
149.79
-10.39% from price
EMA 12
139.18
-3.56% from price
EMA 26
143.11
-6.21% from price
EMA 50
146.64
-8.47% from price
RSI (14)
39.0
Neutral
MACD (12,26,9)
-3.93
Hist -0.27
ATR (14)
4.21
3.14% of price
Realised vol 30D
77.5%
Annualised
Bollinger upper
146.25
20, 2σ
Bollinger lower
132.06
20, 2σ
50 / 200 cross
Golden
149.94 vs 149.79
Trend bias
Below 200
-10.39%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
-0.34
Less volatile than market
Correlation to SPY
-0.09
Largely independent
Realised vol 30D
77.5%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-21.9%
Peak to trough
Max drawdown 5Y
-22.7%
Peak to trough
ATR 14
4.21
3.14% of price
Beta (reported)
0.47
5Y monthly, from filing
Dividends & splits
Forward rate$4.73 / yr
Forward yield3.53%
5-year avg yield3.51%
Payout ratio68.92%
Ex-dividend dateMar 10, 2026
Next pay dateMar 8, 2018
Last split1055:1000
Split dateOct 4, 2023
Headlines
Novartis advances multiple sclerosis innovation with late-breaking remibrutinib and broad portfolio data at MSToronto2026
GlobeNewswire · 32m ago
AI companies run virtual drug trials, aim to improve success of human studies
Reuters · 1h ago
Pacibekitug Market Size, Sales Forecast, and Competitive Analysis - 2034 | Phase III-Ready IL-6 Therapy Targets Major Cardiovascular Growth Opportunities in the 7MM
GlobeNewswire · 3h ago
Novartis (SWX:NOVN) Stock May Trade Below Fair Value As Digital CMC News Lands
Simply Wall St. · 5h ago
Novartis Stocks Stay Flat as $575 Million RNA Bet Opens $7.2 Billion Tail
GuruFocus.com · 16h ago
SAP Puts the Autonomous Enterprise to Work
PR Newswire · 1d ago
Biopharma's Leapfrog Moment: The Launch of the Digital CMC Consortium
PR Newswire · 1d ago
Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen Deal
Zacks · 2d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.